Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Early P 1 (1)
P 1 (3)
P 2 (1)

Trial Status

Not Yet Recruiting3
Active Not Recruiting1
Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT07384715Phase 1RecruitingPrimary

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

NCT07770698Phase 1Not Yet Recruiting

A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia

NCT07766850Phase 1Not Yet RecruitingPrimary

Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia

NCT07651475Phase 2Active Not RecruitingPrimary

Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

NCT07336875Early Phase 1Not Yet RecruitingPrimary

Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML

Showing all 5 trials

Research Network

Activity Timeline